Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
The group’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Their ambition is to become the most influential life science company for researchers worldwide to support research, diagnostic and therapeutic applications.
AB Dynamics was founded in 1982 as a specialist vehicle engineering company and has grown consistently to become one of the world’s most trusted global suppliers of automotive test and verification systems.
The group’s customers include the top 25 global vehicle manufacturers, tier one suppliers, all 8 Euro NCAP laboratories, numerous global test facilities and autonomous vehicle developers. AB Dynamics is playing a key role in the transition towards semi-autonomous and ultimately fully autonomous vehicles.
EMIS Group is a major provider of healthcare software, information technology and related services in the UK. The group’s strategy is a combination of three core parts – connected healthcare, patient empowerment and technology innovation. This powerful combination of priorities means EMIS is able to continually add value to the NHS and B2B healthcare sector.
The group is a regular on the Best Investor Communication shortlist and won the award in both 2018 and 2019.
Oncimmune is leading global immunodiagnostics group with an intimate understanding of the human immune system, enabling the group to detect cancer earlier and support the development of better therapies.
The group launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and is shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis.